Empire Genomics

Executive Summary

Empire Genomics is a US-based biotechnology company that specializes in the development, manufacturing, and distribution of Fluorescence In Situ Hybridization (FISH) probes and related reagents for clinical diagnostics and research. Founded in 2005, the company leverages a proprietary BAC library derived from the Human Genome Project to offer a comprehensive portfolio of both manual and automated FISH solutions. With a focus on accuracy, rapid turnaround, and custom probe design, Empire Genomics serves a global customer base, including top-tier cancer centers. The company's products are critical for the detection of genetic abnormalities, particularly in oncology, and their ability to provide custom probes gives them a competitive edge in personalized medicine. Empire Genomics operates in the stable and growing market of molecular diagnostics, driven by increasing demand for precision medicine and early cancer detection. While the company is private and does not disclose financials, its enduring presence since 2005 suggests a solid business model. Key growth drivers include the expansion of FISH applications in liquid biopsy and companion diagnostics, as well as potential partnerships with pharmaceutical companies for clinical trial assays. However, competition from larger players and alternative technologies (e.g., NGS) poses risks. Overall, Empire Genomics is well-positioned in a niche but essential segment of the diagnostics industry.

Upcoming Catalysts (preview)

• Q4 2026Launch of new automated FISH platform or assay menu expansion60% success
• 2027Strategic partnership with a major cancer center or pharma company for companion diagnostics50% success
• TBDFDA clearance or CE marking for a new diagnostic FISH test40% success